ADAG

About Adagene Inc. American Depositary Shares (ADAG) Stock

Adagene Inc. American Depositary Shares (ADAG) closed the 2026-09-16 session at $3.17, up 6.73% versus the previous close (+0.20). The stock opened at $3.00 and traded between $2.92 and $3.24 during that session. Session trading volume was 319K shares. The volume-weighted average price (VWAP) is $3.14.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

Adagene Inc. American Depositary Shares has a market capitalization of $212.8 million. ADAG is listed on the XNAS exchange. The company employs approximately 128 people. The recorded listing date is 2021-02-09.

On this page you can find market ADAG stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.

Explore more: View today's market movers, use the stock screener, or browse all sectors.